Josep M. Miró

Sobre mí

Publicaciones destacadas

• Characteristics and outcome of acute heart failure in infective endocarditis: focus on cardiogenic shock

  Autores: Pericàs JM, Hernández-Meneses M, Muñoz P, Martínez-Sellés M, Álvarez-Uria A, de Alarcón A, Gutiérrez-Carretero E, Goenaga MA, Zarauza MJ, Falces C, Rodríguez-Esteban MÁ, Hidalgo-Tenorio C, Hernández-Cabrera M, Miró JM, Spanish Collaboration on Endocarditis—Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES).

  Referencia: Clinical Infectious Diseases 2021.

• Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs

  Autores: Pericàs JM, Llopis J, Athan E, Hernández-Meneses M, Hannan MM, Murdoch DR, Kanafani Z, Freiberger T, Strahilevitz J, Fernández-Hidalgo N, Lamas C, Durante-Mangoni E, Tattevin P, Nacinovich F, Chu VH, Miró JM, International Collaboration on Endocarditis (ICE) Investigators.

  Referencia: Journal Of The American College Of Cardiology 2021.

• Infective endocarditis: an ongoing global challenge

  Autores: Miro JM, Ambrosioni J .

  Referencia: European Heart Journal 2019.

• Outpatient Parenteral Antibiotic Treatment (OPAT) for Infective Endocarditis: a Prospective Cohort Study From the GAMES Cohort

  Autores: Pericà S JM, Llopis J, González-Ramallo V, Goenaga MÁ, Muñoz P, García-Leoni ME, Fariñas MC, Pajarón M, Ambrosioni J, Luque R, Goikoetxea J, Oteo JA, Carrizo E, Bodro M, Reguera-Iglesias JM, Navas E, Hidalgo-Tenorio C, Miró JM, Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) investigators.

  Referencia: Clinical Infectious Diseases 2019.

• Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

  Autores: Garcia-de-la-Maria C, Xiong YQ, Pericas JM, Armero Y, Moreno A, Mishra NN, Rybak MJ, Tran TT, Arias CA, Sullam PM, Bayer AS, Miro JM .

  Referencia: Antimicrobial Agents And Chemotherapy 2017.

• HIV Infection Does Not Worsen Prognosis of Liver Transplantation for Hepatocellular Carcinoma

  Autores: Agüero F, Forner A, Manzardo C, Valdivieso A, Blanes M, Barcena R, Rafecas A, Castells L, Abradelo M, Torre-Cisneros J, Gonzalez-Dieguez L, Salcedo M, Serrano T, Jimenez-Perez M, Herrero JI, Gastaca M, Aguilera V, Fabregat J, Del Campo S, Bilbao I, Romero CJ, Moreno A, Rimola A, Miro JM, FIPSE Investigators.

  Referencia: Hepatology 2016.

• Infective endocarditis

  Autores: Holland, Thomas L.; Baddour, Larry M.; Bayer, Arnold S.; Hoen, Bruno; Miro, Jose M.; Fowler, Vance G., Jr.;.

  Referencia: Nature Reviews Disease Primers 2016.

• Short-course antiretroviral therapy in primary HIV infection

  Autores: , Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A SPARTAC Trial Investigators.

  Referencia: New England Journal Of Medicine 2013.

• Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. (vol 43, pg 79,

  Autores: Miro, J. M.; Lopez, J. C.; Podzamczer, D.; Pena, J. M.; Alberdi, J.; Martinez, E.; Domingo, P.; Cosin, J.; Claramonte, X.; Arribas, J. R.; Santin, M.; Ribera, E.;.

  Referencia: Clinical Infectious Diseases 2006.

• Staphylococcus aureus native valve infective endocarditis: Report of 566 episodes from the International Collaboration on Endocarditis Merged Database

  Autores: Miro, JM; Anguera, I; Cabell, CH; Chen, AY; Stafford, JA; Corey, GR; Olaison, L; Eykyn, S; Hoen, B; Abrutyn, E; Raoult, D; Bayer, A; Fowler, VG;Int Collaboration Endocarditis.

  Referencia: Clinical Infectious Diseases 2005.

Proyectos destacados

• In vitro and experimental endocarditis model study of the efficacy of new oral and parenteral combinations of antibiotics for outpatient treatment of infectious endocarditis

  Investigador/a principal: Josep M. Miró Meda

  Código: PI20/00830

  Duración: 01/01/2021 - 31/12/2023

• Prevention of vascular catheter-related infections by the FUNctionalization of CATHeters with thermically activated hydrogels with antimicrobial agents of broad spectrum (FUNCATH).

  Investigador/a principal: Cristina Garcia de la Maria

  Código: 75/C/2018

  Duración: 15/01/2019 - 31/12/2022

• Eficacia de nuevas pautas de tratamiento antibiótico de la endocarditis enterocócica evaluadas in vitro y en el modelo de endocarditis experimental.

  Investigador/a principal: J.M. Miró

  Código: PI17/01251

  Duración: 01/01/2018 - 01/01/2020

• Estudio clínico y experimental de la relación entre la CMI de vancomicina en Staphylococcus aureus sensible a meticilina (SASM) y el pronóstico de la endocarditis infecciosa (EI) izquierda causada SASM

  Investigador/a principal: José María Miró Meda

  Código: 201526 10

  Duración: 01/01/2016 - 01/01/2018

• A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients with Intravenous Catheter associated Blood Stream Infections due to Staphylococci

  Investigador/a principal: José María Miró Meda, Josep M. Miró Meda

  Código: BAA NIAID-DMID-NIH AI 200

  Duración: 01/01/2011 - 31/12/2017